Sugi Predict

Sugi Predict / Compounds / SCHEMBL17396955

SCHEMBL17396955

SCHEMBL17396955

O=C(O)Cc1cc(Br)ccn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.53
▸ ALDH1A1 P00352 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ GABRP O00591 1/20 0.44
▸ GABRD O14764 1/20 0.44
▸ GABRA1 P14867 1/20 0.44
▸ GABRB1 P18505 1/20 0.44
▸ GABRG2 P18507 1/20 0.44
▸ GABRB3 P28472 1/20 0.44
▸ GABRA5 P31644 1/20 0.44
▸ GABRA3 P34903 1/20 0.44
▸ GABRA2 P47869 1/20 0.44
▸ GABRB2 P47870 1/20 0.44
▸ GABRA4 P48169 1/20 0.44
▸ GABRE P78334 1/20 0.44
▸ GABRA6 Q16445 1/20 0.44
▸ GABRG1 Q8N1C3 1/20 0.44
▸ GABRG3 Q99928 1/20 0.44
▸ GABRQ Q9UN88 1/20 0.44
▸ CYP1A2 P05177 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1871113 0.83 KDM4E (0.47) KDM4EALDH1A1SMN1; SMN2GABRPGABRD
SCHEMBL29842314 0.83 KDM4E (0.47) KDM4EALDH1A1SMN1; SMN2GABRPGABRD
SCHEMBL622930 0.83 KDM4E (0.47) KDM4EALDH1A1SMN1; SMN2GABRPGABRD
SCHEMBL12815057 0.81 KDM4E (0.50) KDM4EALDH1A1SMN1; SMN2CYP1A2MAPT
SCHEMBL15489237 0.81 RAB9A (0.49) KDM4EALDH1A1SMN1; SMN2CYP1A2MAPT
SCHEMBL7914812 0.81 GABRP (0.44) KDM4EALDH1A1GABRPGABRDGABRA1
Hydrochloric Acid SCHEMBL27872175 0.79 GABRP (0.43) KDM4EALDH1A1GABRPGABRDGABRA1
SCHEMBL31252708 0.79 KDM4E (0.43) KDM4EALDH1A1SMN1; SMN2CYP1A2MAPT
SCHEMBL30731116 0.79 KDM4E (0.43) KDM4EALDH1A1SMN1; SMN2CYP1A2MAPT
SCHEMBL15709888 0.79 KDM4E (0.43) KDM4EALDH1A1SMN1; SMN2CYP1A2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102977012-B Synthesis method of methyl 4-bromopyridyl-2-formate CHEMFUTURE PHARMATECH JIANGSU LTD 2015-06-03 — — CN claimed
CN-102977012-A Synthesis method of methyl 4-bromopyridyl-2-formate CHEMFUTURE PHARMATECH JIANGSU LTD 2013-03-20 — — CN claimed
US-20240360121-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2024-10-31 — — US disclosed
US-11958849-B2 GLS1 inhibitors for treating disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-04-16 — — US disclosed
US-20230192699-A1 COMPOUNDS AS CASEIN KINASE INHIBITORS Gritscience Biopharmaceuticals Co., Ltd. (CN) 2023-06-22 — — US disclosed
US-20230147993-A1 THIOPHENE COMPOUNDS WITH CYCLIC AMIDES, AND USES THEREOF CAPULUS THERAPEUTICS, LLC 2023-05-11 — — US disclosed
US-20230124815-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2023-04-20 — — US disclosed
US-20230061841-A1 SHMT INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-03-02 — — US disclosed
EP-4097096-A2 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 — — EP disclosed
CN-115335057-A Method for inhibiting casein kinase 北京原基华毅生物科技有限公司 2022-11-11 — — CN disclosed
CN-115298183-A Compounds as casein kinase inhibitors 北京原基华毅生物科技有限公司 2022-11-04 — — CN disclosed
WO-2016004404-A2 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) 2016-01-07 — — WO disclosed
CN-102977012-B Synthesis method of methyl 4-bromopyridyl-2-formate CHEMFUTURE PHARMATECH JIANGSU LTD 2015-06-03 — — CN disclosed
CN-103619817-A Novel bicyclic nitrogen containing heteroaryl TGR5 receptor modulators BRISTOL MYERS SQUIBB CO 2014-03-05 — — CN disclosed
CN-102977012-A Synthesis method of methyl 4-bromopyridyl-2-formate CHEMFUTURE PHARMATECH JIANGSU LTD 2013-03-20 — — CN disclosed
CN-101798298-B Imidazole derivatives HOFFMANN LA ROCHE 2013-01-09 — — CN disclosed
CN-101798298-A Imdazole derivatives HOFFMANN LA ROCHE 2010-08-11 — — CN disclosed
CN-1489580-B Imidazole derivatives HOFFMANN LA ROCHE 2010-05-26 — — CN disclosed
CN-101679408-A Bicyclic heterocyclic compounds as FGFR inhibitors ASTEX THERAPEUTICS LTD 2010-03-24 — — CN disclosed
CN-1489580-A Imidazole derivatives - 2004-04-14 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360121-A1 GLS1 INHIBITORS FOR TREATING DISEASE GLS2, GLS, GLG1 KDM4E 3347/4885ALDH1A1 882/4885SMN1; SMN2 2191/4885
US-20230124815-A1 GLS1 INHIBITORS FOR TREATING DISEASE GLS2, GLS, GLG1 KDM4E 3347/4885ALDH1A1 882/4885SMN1; SMN2 2191/4885
US-20230061841-A1 SHMT INHIBITORS AND USES THEREOF SHMT1, SHMT2, BHMT KDM4E 344/4885ALDH1A1 189/4885SMN1; SMN2 4027/4885
US-20230147993-A1 THIOPHENE COMPOUNDS WITH CYCLIC AMIDES, AND USES THEREOF SREBF1, SREBF2, FABP1 KDM4E 2416/4885ALDH1A1 2332/4885SMN1; SMN2 3940/4885
US-11958849-B2 GLS1 inhibitors for treating disease GLS2, GLS, GLG1 KDM4E 3347/4885ALDH1A1 882/4885SMN1; SMN2 2191/4885
US-20230192699-A1 COMPOUNDS AS CASEIN KINASE INHIBITORS CSNK2A3, CSNK1A1, CSNK1G3 KDM4E 836/4885ALDH1A1 4585/4885SMN1; SMN2 3301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback